

# Who is the leem?

The Leem is the **French industry association** which represents **drug companies operating in France.**



## Representing and defending the pharmaceutical industry

The Leem has over **280 member companies** representing a total workforce of **106.038 employees** (more than 3,3% of industrial employment in France) and a revenue of more than **€ 70 billion** (of which half are exports).

The industry association provides its members with in-depth, quantified and well-reasoned **studies and analyses** on current events and on major issues facing by the **drug industry**. On a national level, Leem **acts as a union and advocate for the pharmaceutical industry**. In this capacity, it participates in numerous **official, ministerial and inter-ministerial committees**. Leem is a member of the **French Federation of Healthcare Industries (FEFIS)** and of the **French Enterprise Movement (MEDEF)**. At international level, Leem is a member of the **European Federation of Pharmaceutical Associations and Industries (EFPIA)** and of the **International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)**.

The Leem as also created a panel of **9 different commissions and 28 committees** that follow the main concerns and trends of the industry. They allow the Leem to make important decisions with the agreement of different actors of the industry and to define orientation for future projects.



## Engaging in agreement-based policy with the State

Every three years since 1994, the Leem has negotiated the **agreement-based policy with the State** for the **price setting and regulation of medicines** in France through a “framework agreement”. The latest policy, signed in March 2021, provides the government and pharmaceutical companies with a solid basis to **address the issue of innovative treatment pricing**.

As the interlocutor between industry and policy makers, Leem is the driving force behind proposals to promote France’s attractiveness as an industrial hub and to pursue a healthcare policy geared towards patients’ needs, while preserving the benefits delivered by innovative therapies as well as the healthcare spending control target.



## Negotiating with social partners

Leem is the only **pharmaceutical employers’ association in France** and, as such, engages in **social policy work** on behalf of the sector, **negotiating**, among other things, the **collective agreement or minimum wage agreements** with social partners.



## Promoting and defending ethical standards

In its promotion of **responsible conduct** within the healthcare system, Leem is committed to a **CSR policy** that has been jointly developed by society and industry stakeholder’s. The first industry association to sign the **Joint Statement of Transparency International France on Ethical and Responsible Lobbying** (July 2015), Leem is working to ensure that pharmaceutical companies **uphold the standards of professional ethics**.

Through the **Conduct and Ethics Committee of the French Association of Pharmaceutical Companies (Codeem)**, which was set up in 2011, it provides **ethical oversight, promotes awareness and proposes professional guidelines** to its member companies (protection of whistleblowers, clarification on conflicts of interest, etc.) and has powers to impose **sanctions** when the rules of ethics are breached.



## A territorial presence for a collective sector stake

The Leem ensures a **territorial presence** and fosters a **dynamic industry ecosystem** with all stakeholders. This allows the Leem to form groups of actors who collaborate and adhere with each other. By organizing collaborative and exchange groups, we strengthen the connection between **industry players**, leveraging Leem’s expertise to support **the development ambitions** of our sector.

Territorial anchoring is also a significant development focus : serving the pharmaceutical industry means **working alongside economic and political actors in the regions**.

